NextCure, a clinical-stage biotech developing cancer immunotherapies, announced terms for its IPO on Monday.
The Beltsville, MD-based company plans to raise $75 million by offering 5 million shares at a price range of $14 to $16. At the midpoint of the proposed range, NextCure would command a fully diluted market value of $350 million.
NextCure was founded in 2015 and plans to list on the Nasdaq under the symbol NXTC. Morgan Stanley, BofA Merrill Lynch and Piper Jaffray are the joint bookrunners on the deal. It is expected to price during the week of May 6, 2019.
